Korea Investment CORP Takes Position in Edwards Lifesciences Corporation $EW

Korea Investment CORP purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 447,558 shares of the medical research company’s stock, valued at approximately $40,486,000. Korea Investment CORP owned about 0.08% of Edwards Lifesciences as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the second quarter valued at about $3,410,000. Ieq Capital LLC bought a new position in Edwards Lifesciences during the second quarter worth about $10,075,000. Callan Family Office LLC bought a new position in Edwards Lifesciences during the second quarter worth about $2,247,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $39,000. Finally, Allworth Financial LP acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $1,502,000. 79.46% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EW has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Evercore reissued an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Citigroup increased their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Up 0.1%

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The business has a 50-day moving average of $89.21 and a two-hundred day moving average of $84.67. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the previous year, the business posted $0.67 EPS. Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.